Human T lymphotropic virus type 1 (HTLV-1) causes disabling and fatal diseases, yet there
is no vaccine, no satisfactory treatment, and no means of assessing the risk of disease or …

The first description of the human T-lymphotropic virus type 1 (HTLV-1) was made in 1980,
followed closely by the discovery of HTLV-2, in 1982. Since then, the main characteristics of …

Human T-lymphotropic virus types I and II (HTLV-I and-II) cause myelopathy; HTLV-I, but not
HTLV-II, causes adult T-cell leukemia. Whether HTLV-II is associated with other diseases is …

BACKGROUND: Mashhad, in the northeast of Iran has been suggested as an endemic area
for human T cell lymphotropic virus type I (HTLV-I) infection since 1996. OBJECTIVES: We …

Mother-to-child transmission (MTCT) of Human T-cell lymphotropic virus type 1 (HTLV-1)
causes lifelong infection. At least 5–10 million individuals worldwide are currently living with …

Human T-cell leukemia virus type 1 (HTLV-1) is the causative agent of a neural chronic
inflammation, called HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) …

Human T-cell lymphotropic viruses 1 and 2 (HTLV-1/2) are relatively common in Brazil but
remain silent and neglected infections. HTLV-1 is associated with a range of diseases with …

Human T-cell leukemia virus type 1 (HTLV-1), the first human retrovirus to be discovered, is
present in diverse regions of the world, where its infection is usually neglected in health care …

The African continent is considered the largest high endemic area for the oncogenic
retrovirus HTLV-1 with an estimated two to five million infected individuals. However, data on …

Many countries currently perform antibody screening for HTLV-1 infection in blood donors,
and this intervention is likely cost-effective in preventing HTLV-1 related diseases in high …